Skip to main content

Table 1 Study assessments

From: Life style and interaction with microbiota in prostate cancer patients undergoing radiotherapy: study protocol for a randomized controlled trial

Assessment

Instruments

Visits

Baseline

After RT

T6

T12

T18b

Heighta, weight, waist and hip circumference, Body Mass Index

Calibrated scales, stadiometer, tape measures

✓

✓

✓

✓

✓

Heart rate and blood oxygen saturation

Finger pulse oximeter

✓

✓

✓

✓

✓

Total, HDL, LDL cholesterol, triglycerides, glucose, insulin, PSA, and other serum biomarkersc

Blood Sample

✓

 

✓

✓

✓

Intestinal microbiome composition

Fecal Sample

✓

✓

✓

✓

✓

Body composition

BIVA (Bioelectrical Impedance Vector Analysis – Nutrilab device AKERN Srl – Italy)

✓

✓

✓

✓

✓

Food consumption

16-items Dietary Questionnaire

✓

✓

✓

✓

✓

Physical activity

International Physical Activity Questionnaire (IPAQ)

✓

✓

✓

✓

✓

Steps

Pedometer-like device (wrist band)

IG

–

CG

–

–

Quality of Life

Functional Assessment on Cancer Therapy (FACT-P)

✓

–

✓

✓

✓

Self-efficacy

Self-Efficacy Scale (GS-EF)

✓

–

✓

✓

✓

Anxiety

Anxiety Scale for Prostate Cancer (MAX – PC)

✓

–

✓

✓

✓

Life orientation

Life Orientation test (LOT-R)

✓

–

✓

✓

✓

Personality traits

Personal Traits Questionnaire (Con-OR)

✓

–

✓

✓

✓

Patient reported acute and late toxicity

Questionnaire acute and late toxicity

✓

✓

✓

✓

✓

Erectile function

International Index of Erectile Function (IEEF)

✓

✓

✓

✓

✓

Urinary function

International Prostate Symptoms Score (IPSS), International Consultation on Incontinence Questionnaire (ICIQ-SF)

✓

✓

✓

✓

✓

Acute and late toxicity

RTOG/EORTCd

✓

✓

✓

✓

✓

  1. a- Height will be assessed only at baseline; b T18 visit is planned only for control group; c Other serum biomarkers: testosterone, estradiol, sex hormone binding globulin, high sensitive C-reactive protein (hs-CRP), adiponectin, 25-hydroxy vitamin D, Interleukin-6 (IL-6), Luteinizing hormone (LH); d Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)